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Abstract
AIM: To investigated the performance of the tissue 
resonance interaction method (TRIM) for the non-
invasive detection of colon lesions.
METHODS: We performed a prospective single-center 
blinded pilot study of consecutive adults undergoing 
colonoscopy at the University Hospital in Sassari, Italy. 
Before patients underwent colonoscopy, they were 
examined by the TRIMprobe which detects differences 
in electromagnetic properties between pathological 
and normal tissues. All patients had completed the 
polyethylene glycol-containing bowel prep for the 
colonoscopy procedure before being screened. During 
the procedure the subjects remained fully dressed. A 
hand-held probe was moved over the abdomen and 
variations in electromagnetic signals were recorded 
for 3 spectral lines (462-465 MHz, 930 MHz, and 
1395 MHz). A single investigator, blind to any clinical 
information, performed the test using the TRIMprob 
system. Abnormal signals were identified and recorded 
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as malignant or benign (adenoma or hyperplastic 
polyps). Findings were compared with those from 
colonoscopy with histologic confirmation. Statistical 
analysis was performed by χ 2 test.
RESULTS: A total of 305 consecutive patients fulfilling 
the inclusion criteria were enrolled over a period of 12 
months. The most frequent indication for colonoscopy 
was abdominal pain (33%). The TRIMprob was 
well accepted by all patients; none spontaneously 
complained about the procedure, and no adverse 
effects were observed. TRIM proved inaccurate for 
polyp detection in patients with inflammatory bowel 
disease (IBD) and they were excluded leaving 281 
subjects (mean age 59 ± 13 years; 107 males). The 
TRIM detected and accurately characterized all 12 
adenocarcinomas and 135/137 polyps (98.5%) including 
64 adenomatous (100%) found. The method identified 
cancers and polyps with 98.7% sensitivity, 96.2% 
specificity, and 97.5% diagnostic accuracy, compared 
to colonoscopy and histology analyses. The positive 
predictive value was 96.7% and the negative predictive 
value 98.4%. Among the 281 non-IBD subjects, there 
were 7 cases with discordant results (2.5%) between 
TRIMprob and the reference standard including 5 false 
positive results (1.8%) and 2 false negative (0.7%) 
results. The main limitation of the TRIMprob system is 
the need for trained operators.
CONCLUSION: The study confirmed that TRIM pr-
ovides rapid, accurate, convenient and noninvasive 
means to identify individuals most likely to benefit 
from colonoscopy.
Key words: Colon cancer screening; Bioscanner; non-
invasive diagnosis; Electromagnetic; Resonance
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Core tip: In this study we evaluated the potential 
role of a non-invasive method: the tissue resonance 
interaction method or TRIMprob, for enriching the 
population for colonoscopy with patients most likely 
to benefit. The apparatus was initially developed by 
the Italian scientist Clarbruno Vedruccio for military 
purpose and is another example of technology 
originally developed for military purpose adapted 
for medical use. The method is designed to detect 
differences in electromagnetic properties of pathologic 
and normal tissues and is currently being used in 
cancer detection in a number of other organs. The 
sensitivity, specificity and accuracy of the TRIMprob 
for detecting and correctly identifying colon cancer 
or polyps compared to endoscopy with histological 
examination were greater than 95%.
Dore MP, Tufano MO, Pes GM, Cuccu M, Farina V, Manca A, 
Graham DY. Tissue resonance interaction accurately detects 
colon lesions: A double-blind pilot study. World J Gastroenterol 
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INTRODUCTION
Colon rectal cancer (CRC) is a common disease world­
wide and is associated with a high morbidity and 
mortality[1]. Despite improvement in cancer detection 
and treatment, the American Cancer Society estimated 
that more than 50 thousand of Americans would 
die of CRC in 2013[2]. Clinical outcomes in CRC are 
closely related to the stage of the disease at presenta­
tion. Current colon cancer prevention programs are 
predicated on identifying and removing premalignant 
and malignant lesions curable by local resection. 
Population screening with fecal occult blood testing, 
endoscopy, or radiology are currently being used in an 
attempt to reduce both the incidence and mortality from 
CRC[3].
Colonoscopy is currently the single best diagnostic 
test since it can identify, biopsy, and remove lesions 
throughout the large bowel[4]. Because most CRC are 
thought to develop from adenomas, the detection and 
removal of premalignant polyps has the potential, and 
has been proven, to reduce deaths from CRC. Despite 
major programs for CRC screening in many countries, 
approximately 50% of the cases of colon cancer are 
still diagnosed at a late stage[5], and test utilization is 
largely influenced by demographic and social-cultural 
factors[6].
Ongoing research to identify methods to enrich the 
proportion of patients with positive findings among 
the population undergoing colonoscopy have included 
development of improved methods for detection of fecal 
occult bleeding and fecal DNA testing[7]. A potential 
alternate approach, as described here, is based on 
an electronic device employing frequency­selective 
(resonant) absorption of electromagnetic waves 
capable of detecting biological anomalies in tissue in 
vivo such as inflammation, fibrosis, and malignant solid 
tumors developed by the Italian physicist, Clarbruno 
Vedruccio[8,9]. This technology uses a non­linear 
radiofrequency oscillator probe emitting electromagnetic 
waves at 462­465, 930, and 1395 MHz, plus harmonics 
as previously described[10,11]. This non­linear resonance 
interaction provides a selective characterization, 
that can be likened to an “electronic biopsy” of the 
tissues. The biophysical mechanisms responsible for 
differences in electromagnetic waves absorption have 
not yet been entirely elucidated. In the case of cancer, 
Pokorný et al[12] proposed that the effect is related 
to a mitochondrial malfunction (the Warburg effect) 
associated with increased damping of microtubule­
based cellular elasto­electrical vibration states[13,14]. The 
principle of detection lies in the resonance between 
the coupled active nonlinear oscillator (the probe) and 
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the passive oscillator (the tissue) in the radiofrequency 
range of the electromagnetic spectrum. Tissue 
suspected of harboring disease is irradiated by means 
of a hand­held probe placed 1 to 2 m from the patient, 
captured by using a special antenna and analyzed 
through a spectrum analyzer (Figure 1). The device 
has a high dynamic range, in the order of 30 decibel 
(dBm) or more, and can thus detect small lesions[8,15,16]. 
Originally the apparatus was developed for military 
purposes and is another example of technology being 
adapted for medical use.
Prior clinical experience with the TRIMprob has 
proven the method to be simple and reliable with 
high diagnostic yield when used for detection of 
prostate[9,15­17], breast[18], and bladder cancers[19], thyroid 
carcinoma in patients with multinodular goiter[20], 
gastric cancer[21], and rectal cancer[22]. The aim of this 
study was to extend the use of the TRIMprob to the 
non­invasive detection of colon lesions. We therefore 
compared the TRIMprob method for detection of colonic 




This was a prospective single­center, operator­blinded, 
pilot study. The clinicians, endoscopists and TRIMprob 
operator remained blinded to the results of the 
alternate method until the study was completed.
Inclusion criteria
Consecutive patients aged 18 years and older att­
ending the general gastroenterology section at the 
University Hospital in Sassari, Italy (Clinica Medica), 
with an indication for colonoscopy for any reason, were 
invited to participate.
Exclusion criteria
Patients with an implanted pacemaker and pregnant 
women.
Ethics statement
Written informed consent was obtained from each 
participant. The study protocol was approved by the 
Local Ethics Committee, more specifically by the 
“Comitato di Bioetica dell’Azienda Sanitaria Locale 
(A.S.L.) n° 1 di Sassari” (supplemental material, 
Appendix 1). There was no device company or com­
mercial sponsor for this study.
TRIMprob examination
The system consists of a work­station plus a battery 
powered hand­held probe 30 cm long with a tunable, 
autonomous, non linear oscillator that emits low 
intensity electromagnetic waves (similar to that 
experienced during the use of a cordless telephone). 
The work station is composed by a personal computer 
assisted spectrum analyzer­receiver to process and 
display the interaction between the radiofrequency 
probe emission and the diseased tissue (Figure 2).
In this study, a hand­held computer (PSA2701T­2.7 
GHz RF Spectrum Analyzer Thurlby Thandar Instru­
ments, Ltd, Huntingdon, United Kingdom), was added 
to the system; wave variations were displayed on the 
personal computer screen using a logarithmic scale 
and expressed in arbitrary units of 0­255 and also 
in decibel (dBm) by the hand­held computer based 
spectrum analyzer to facilitate signal interpretation by 
the operator (Figure 1).
A single investigator (MOT), blind to any clinical 
information, performed the test using the TRIMprob 
system (Galileo Avionica, Turin, Italy) approved by 
the “Ministero della Salute” (corresponding to the 
Italian FDA) as a medical device, and certified by the 
European Union (supplemental material, Appendix 
2­4). The operator is a physician radiologist with 
expertise in ultrasound and specifically trained on the 
TRIMprob system with a multi­organ experience of 
more than 10 thousand TRIMprob examinations.
The test was performed approximately 15 min 
before the scheduled colonoscopy. All patients had 
completed the polyethylene glycol (PEG)­containing 
bowel prep for the colonoscopy procedure before being 
screened by the TRIM system. During the procedure 
the subjects remained fully dressed. The probe was 
Figure 1  colon area is scanned with the TRIMprob while the patient 
remains normally dressed and standing approximately 2 m in front of the 




Figure 2  TRIMprob Medical Device. The system is composed of the 
exploratory probe, the receiver (a spectrum analyzer), and a computer with 
dedicated software to record patient information and store TRIMprob data.
Dore MP et al . Screening of colon lesions
Table 1  Results of the preliminary study to establish criteria for the outcomes assessed in the blinded trial
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moved over the surface of the abdomen (Figure 1), 
from the upper to the lower right and left quadrants 
of the abdomen, including the pelvic area in order to 
perform a complete examination of the colon segments 
and rectum. In addition, the perineal area was screened 
in order to exclude malignancies from the uterus or 
prostate.
The colon was irradiated through the abdomen wall 
by the field resulting from the TRIM antenna. Nonlinear 
resonance interactions between the nonlinear oscillator 
and the tissue reduce the emitted wave energy at 
distinct frequencies on the basis of the pathological 
state of the tissue being examined and a reduction in 
signal amplitude indicates the presence of abnormal 
tissues or structures. Amplitude changes of the emitted 
signals at the established frequencies of 465, 930, and 
1395 MHz were recorded in an electronic file as a value 
of the corresponding spectral line expressed in decibel, 
for each position. The entire patient examination took 
8 ± 1.5 min.
Colonoscopy
Patients were provided written and verbal instructions 
about bowel preparation. The conventional four 
liter­dose PEG regimen combined with a strict liquid 
diet for a full day was used (supplemental material, 
Appendix 5).
Polyp size was assessed by comparing the polyp 
dimensions with the maximum jaw width of a fully 
open biopsy forceps (9 mm). Polyps equal to or 
smaller than one­half of the distance between the tips 
of the open biopsy forceps were termed diminutive 
polyps (≤ 5 mm), polyps between 6­9 mm small 
polyps, and those greater in size were considered as 
clinically significant polyps. Attempts were made to 
remove and retrieve all polyps irrespective of size and 
these, as well as biopsies from suspected cancers and 
other mucosal abnormalities, were sent for histological 
evaluation. Diminutive and small polyps were also 
recorded and biopsied or cold snared.
Historically, in our endoscopic unit cecal intubation 
had ranged from 95% to 97%. The proportion 
of polyps of all types identified in 100 screening 
colonoscopies in our population, for which there is 




A preliminary study was done prior to starting the 
blinded study and included 100 patients and 10 stool 
samples which were examined in vitro to determine 
the best threshold values for each of the three spectral 
lines using Receiver Operator Characteristics curves. 
The best cut­off for each frequency was determined 
by maximizing the sum of sensitivity + specificity 
(supplemental material, Appendix 6). Results of the 
interactions between the electromagnetic field emitted 
by the probe and normal/pathological tissue are shown 
in Table 1.
Sessile serrated adenoma/polyps were not found 
in this cohort of patients independently evaluated. The 
presence of stool appears as a decrease of 25 dBm in 
the first spectral line.
Analysis of the data from the blinded trial: The 
results of TRIMprob analysis were compared to that 
of the reference gold standard in a 2 × 2 contingency 
table, the absolute number of true positives (TPs), 
false positives (FPs), true negatives (TNs), and false 
negatives (FNs) was determined. The sensitivity, 
specificity, positive predictive value (PPV) and negative 
predictive value (NPV) of the TRIM procedure compared 
to the gold standard (colonoscopy with histologic 
confirmation) were calculated and 95% confidence 
intervals (CI) were estimated with the Wilson score 
method[23]. The Matthews correlation coefficient (MCC) 
was calculated[24], as a balanced measure of agreement 
between the two methods under comparison. For each 
study participant the most advanced colon lesion was 
considered in order to assign the patient to a diagnostic 
category. All analyses were performed with the SPSS 
statistical package (v. 16.0, Chicago, United States) 
and P­values lower or equal than 0.05 were considered 
statistically significant. The statistical review of the 
study was performed by a biomedical statistician. This 
report was done following STARD guidelines[25].
RESULTS
A total of 305 consecutive patients fulfilling the inclusion 






(n  = 47) (n  = 29) (n  = 16) (n  = 4) (n  = 10)
465 MHz 0 0 25-30 30-35 60-70
930 MHz 0 > 40 > 40 > 40 35-45
1395 MHz 0 0 0-10 65-70 35-45
1Low-grade dysplasia; 2High-grade dysplasia. Threshold values are represented in decibel by the hand-held computer (PSA2701T-2.7 GHz RF Spectrum 
Analyzer Thurlby Thandar Instruments, Ltd, Huntingdon, United Kingdom), spectrum analyzer, for each of the three spectral lines for normal and specific 
biological anomaly of colonic mucosa.
Dore MP et al . Screening of colon lesions
Table 2  Sensitivity, specificity, positive and negative predictive value of the TRIMprob analysis compared to the gold standard 
(colonoscopy and histology) in detecting biological anomalies of colonic mucosa for the whole cohort, and for the non-inflammatory 
bowel disease cohort
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criteria were enrolled over a period of 12 mo. Patients 
were scheduled for colonoscopy for a variety of reasons 
(supplemental material Appendix 7).
The TRIMprob was well accepted by all patients, 
none spontaneously complained about the procedure, 
and no adverse effects were observed. Cecal intubation 
was performed in all patients, however in 10 cecum 
visualization was suboptimal because of a poor bowel 
prep.
TRIM proved inaccurate for polyp detection in 
patients with inflammatory bowel disease (IBD) 
likely because mucosal inflammation produced false 
positive results for polyps. Because IBD patients are 
not candidates for routine screening colonoscopy of 
normal patients, the analysis was performed both on 
all patients examined and separately without the 24 
IBD patients to provide a better approximation of the 
intended population (Table 2) (i.e., as an adjunct to 
screening colonoscopy). Overall, the results were similar 
whether the IBD patients were included or excluded. 
Additional material about IBD patients is provided in the 
online supplemental material (Appendix 8).
Comparison of colonoscopy and TRIMprob
In the 281 non­IBD patients TRIM was able to detected 
all adenocarcinomas (12: 3 were Tis; 4 were T1 N0 
M0; 2 were T2 N0 M0; 2 Any T N M0; Any T Any N 
M1b respectively) (Figure 3), and 135 of 137 polyps 
(98.5%) (including 100% of the 64 adenomas) found 
at colonoscopy (supplemental material, Appendix 9). 
Among the 135 polyps detected, TRIMprob was able 
to correctly categorize 125 (Table 2). Ten TRIMprob 
diagnoses of the polyp histology were incorrect: 5 
adenomas were thought to be hyperplastic polyps 
and 2 adenomas were recognized as adenomas 
but thought to be advanced adenomas. Among the 
advanced adenomas 2 were falsely characterized as 
hyperplastic polyps and 1 as an adenoma.
Sensitivity and specificity
Assuming colonoscopy/histology as the gold standard 
for detecting adenomas, the overall sensitivity, 
specificity, positive and negative predictive values 
of TRIMprob among the non­IBD patients were 
98.7%, 96.2%, 96.7%, and 98.4%. For the entire 
group examined the results were: sensitivity 98.7%; 
specificity 91.9%, positive and negative predictive 
value 92.8% and 98.6% respectively (Table 2).
Discordant cases
Among the 281 non­IBD subjects, there were 7 cases 
with discordant results (2.5%) between TRIMprob and 
the reference standard including 5 false positive results 
(1.8%) and 2 false negative (0.7%) results (Table 3).
False positive TRIMprob
The 5 false positives that were not confirmed by the 
colonoscopy included one thought to be an advanced 
adenoma in the transverse and 4 thought to be 
hyperplastic polyps. There were no false positives 
for the presence of cancer. Importantly, second look 
endoscopy was not done to confirm that the false 
positive results were truly false positive results.
False negative TRIMprob
Two patients had hyperplastic polyps that went 
undetected. Both were between 6 and 9 mm and 
located in the sigmoid colon. One possible speculation 
could be a difficult niche, or the small size of the polyp 
and subsequent studies will need to look specifically at 
this region of the colon.
Patients with poor bowel prep: In the 10 patients 
with a poor bowel prep there were no false positive or 
Histology Colonoscopy 
(No. of positive cases/
total No. of cases)
TRIMProb









All cases 156/305 154 12 2 137 98.7 91.9 92.8 98.6
(IBD + Non IBD) (95.4-99.6) (86.4-95.3) (87.8-95.8) (94.9-99.6)
Non IBD cases 149/281 147   5 2 127 98.7 96.2 96.7 98.4
(95.2-99.6) (91.4-98.4) (92.5-98.6) (94.5-99.6)
Hyperplastic1   73/281   71   4 2 204 97.3 98.1 94.7 99
(90.5-99.2) (95.2-99.2) (87.0-97.9) (96.5-99.7)
Adenomas2   47/281   40   4 7 230 85.1 98.3 90.9 97
(72.3-92.6) (95.7-99.3) (78.8-96.4) (94.0-98.6)
Advanced adenomas3   17/281   14   1 3 263 82.4 99.6 93.3 98.9
(58.9-93.8) (97.9-99.9) (70.2-98.8) (96.7-99.6)
Cancer   12/281   12   0 0 269 100 100 100 100
(75.7-100.0) (98.5-100.0) (75.7-100.0) (98.6-100.0)
1Hyperplastic polyps of every size; 2Every size adenomas with tubular or villus morphology and low grade dysplasia; 3Every size adenomas with tubular or 
villus morphology and high grade dysplasia. TP: True positives; FP: False positive; TN: True negative; FN: False negative; IBD: Inflammatory bowel disease.
Dore MP et al . Screening of colon lesions
Table 3  Two hundred eighty-one non-inflammatory bowel disease subjects
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false negative TRIMprob results. All patients with poor 
bowel preps had the colonoscopy repeated without 
additional finding.
The TRIMprob test displayed good performance 
distinguishing the number of polyps (supplemental 
material, Appendix 10). The consistency between the 
TRIM assay and the colonoscopy/histology was high as 
reflected by a Matthews correlation coefficient (MCC) 
of 0.897.
DISCUSSION
Adenoma detection and removal is one of the primary 
targets for prevention of CRC[4]. Currently, colonoscopy 
is the best available screening tool because it can 
both detect and remove precancerous lesions[4]. 
However, colonoscopy is labor intensive, expensive, 
and its availability is considerably less than the 
size of the population at risk. Attempts have been 
made to enrich the screening population in terms of 
significant abnormalities by the use of fecal occult 
blood testing (FOBT), fecal DNA testing, or computed 
tomographic (CT) colonography[26]. However, FOBT 
has a relatively poor sensitivity for adenoma detection 
and CT colonography is associated with significant 
radiation[27­30].
Figure 3  colon cancer as observed by colonoscopy and by the TRIMprob. Spectral lines A, B and C correspond to the red, green and blue bars respectively in 
D. The interaction between the electromagnetic field emitted by the probe and cancerous tissue results in a significant decrease of 40 dBm at 465 MHz (first spectral 
line), a modest attenuation at 930 MHz (second spectral line); and at 1395 MHz (third spectral line).
Max freq 1: 146
Max freq 2: 59



































281 non-IBD patients Normal Hyperplasia LGD HGD Cancer Total
Colonoscopy
   Normal 127   2   0   0   0 129
   Hyperplasia     0 73   5   2   0   80
   LGD     4   0 40   1   0   45
TRIM
   HGD     1   0   0 14   0   15
   Cancer     0   0   0   0 12   12
   Total 132 75 45 17 12 281
LGD: Low grade dysplasia; HGD: High grade dysplasia; TRIM: Tissue Resonance Interaction Method; IBD: Inflammatory bowel disease.
D
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This pilot study evaluated a non­invasive detection 
method to identify premalignant and malignant 
colon lesions. Compared with colonoscopy/histology 
TRIMprob yielded a sensitivity as high as 98.7% with 
a high concordance (up to 90%) between the two 
methods. These results are similar to those reported 
for use of the TRIMprob method in prostate cancer 
(95.5%­86%)[9,15­17], breast cancer (84%)[18], for 
carcinomas detection in patients with multinodular 
goiter (100%)[20], gastric cancer (100%)[21], and for 
rectal malignant lesions (94%)[22]. More specifically in 
that pilot study, Vannelli et al[22] reported a diagnostic 
accuracy of the TRIMprob of 89.5% when a cutoff 
of 50 arbitrary units was chosen for the 465­MHz 
frequency. The specificity was 85.1% and lower than 
what was observed in our study (97.5%) suggesting a 
lower proportion of false positive attributable to a more 
expert operator[22].
For bladder cancer the level of agreement between 
TRIMprob and cystoscopy was also high (Cohen’s K = 
0.77, P < 0.001)[19].
In this preliminary study, false­negative results 
among the non­IBD patients consisted of 2 cases 
thought to have hyperplastic polyps (0.7%). There 
was 100% TRIM­endoscopy concordance for actual 
cancers. One other case had a false positive diagnosis 
of an advanced adenoma that was not confirmed at 
the blinded endoscopy. Endoscopy was however not 
repeated to ensure that it was a true false positive 
result. In ten cases TRIM was able to detect benign 
lesions but failed to correctly categorize the type of 
benign polyp histologically.
This study was designed to evaluate the accuracy 
of the TRIM approach for identifying and correctly 
categorizing colonic lesions in a mixed population 
scheduled for endoscopy for any reason with the goal 
to detect polyps or cancer and thus potentially reduce 
the incidence of negative colons. The study was not 
restricted to those meeting the criteria for screening 
and contained patients with indications for colonoscopy 
which is likely responsible for the higher prevalence of 
CRC detected.
The TRIMprob demonstrated to provide excellent 
results except in patients with ulcerative colitis or 
Crohn’s disease where 7 of the 24 subjects had 
false positive results for polyps. IBD patients have 
marked mucosal inflammation and those with Crohn’s 
disease have full bowel wall thickness inflammation. 
As this group of patients is markedly different from 
healthy subjects who would participate in colon 
cancer screening in retrospect, they should not have 
been included. However, the data with and without 
IBD patients is given. Future studies will be required 
to determine what is responsible for the TRIMprob 
findings in IBD patients and include comparisons of 
the histology and radiologic findings in the areas with 
TRIMprob abnormalities.
One limitation of the TRIMprob system is the 
requirement for trained operators but this requirement 
is no different from any diagnostic technique including 
colonoscopy. Those who are already expert in inter­
preting ultrasound, computer tomography or magnetic 
resonance images should be able to quickly become 
proficient in this technology. Interobserver evaluations 
of trained TRIMprob operators for other indications 
have shown excellent correlations close to 100%[9,17]. 
These data suggest that developing a cadre of 
individuals with expertise in colon screening should not 
be a major problem.
The probe oscillations of biological tissues produce 
the phenomenon of “non linear resonance interaction’’ 
which is detected by the TRIM receiver. Because the 
required intensities of the electromagnetic waves are 
very low, there is thought to be no health hazard. The 
current price of the TRIMprob system is about € 60000. 
For the single patients we can hypothesize, at least in 
Europe, a cost no more expensive than an abdominal 
ultrasound (€ 100). An additional side benefit of the 
device is the possibility to detect other potential lesions 
located in the scanned areas, regardless of their origin.
Our results should encourage additional studies 
with different designs to confirm these results and 
explore other parameters. For example, to examine 
the need for the colon prep one might examine 
patients scheduled for screening endoscopy (e.g., one 
might perform TRIM before colon prep, immediately 
following the colon prep, and then perform the 
screening endoscopy). Those with positive TRIM but 
negative colonoscopy could be identified immediately 
after the procedure such as by opening a sealed 
opaque envelope to allow immediate comparison 
prompting the endoscopist to reevaluate a certain 
segment of the colon where lesions were identified but 
not seen on endoscopy. Alternate designs would couple 
TRIM with iFOBT to ask whether the combination 
would be complementary for identification of those 
most likely to benefit from colonoscopy. Other areas 
of research include evaluation of methods to automate 
the interpretation of the TRIMprob results and thus 
reduce the need for highly trained operators.
Overall our results are consistent with the notion 
that the non­invasive TRIMprob method is a novel, 
highly effective method for identifying which patients 
would likely benefit most from colonoscopy. The 
TRIMprob examination has the potential to become 
a first line tool in the armamentarium for CRC pre­
vention. TRIMprob colon screening virtually offers an 
inexpensive, noninvasive approach that could make 
colonoscopic screening both more efficient and cost 
effective. Future research includes development of 
software to analyze the images to reduce the need 
for highly trained operators as well testing whether a 
bowel prep is needed prior to TRIM screening.
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the preferred modality of screening, although associated with high costs and 
low patient compliance. Recently, a non invasive device was developed for 
detecting differences in electromagnetic properties of cancerous and normal 
tissues, using a non linear tuneable oscillator, the tissue resonance interaction 
method (TRIM) that proved to accurately identify those patients who would 
likely benefit from colonoscopy.
Research frontiers
The diagnosis of cancer in humans is mainly based on morphological changes 
in cells and irregularities in tissues confirmed using cytological and histological 
methods. The TRIMprob focuses on differences in the biochemical metabolism 
between cancer and normal cells which produce electromagnetic fields 
inducing alignment in dipole movements. Most of the molecules in the body are 
electrical dipoles which electronically function like transducers in that they are 
able to transform acoustic waves into electrical waves and electrical waves into 
acoustic waves. The natural properties of biomolecular structures enable cell 
components and whole cells to oscillate and interact resonantly with other cells. 
The cells of the body and cellular components possess the ability to function as 
electrical resonators. A dipole movement is a function of polarization processes 
and the strength of the electric field. When cell membranes in the biological 
tissue are exposed to an electric field in the right frequency and amplitude 
windows a preferential alignment of dipoles occurs. TRIMprob utilizes frequency 
selective (resonant) absorption of electromagnetic waves in malignant tumors. 
The biochemical interactions are dislodged from electromagnetic fields in this 
way the TRIMprob represents a revolution in devising a new way of screening. 
This method has previously been proven to be highly accurate in detection of 
other cancers such as breast and prostate.
Innovations and breakthroughs
Colorectal cancer is one of the most common malignancies. Current colon 
cancer prevention programs focus on polyp detection and removal and 
detection of early cancers using colonoscopy to reduce cancer incidence and 
mortality. However, colonoscopy is associated with high costs, poor patient 
acceptability, and the majority of examinations are negative making the method 
very inefficient. A method to non-invasively detect lesions would allow to target 
colonoscopy to those who would most likely benefit. Here, the authors show 
that using a non-linear tunable oscillator to detect differences in electromagnetic 
properties of biological abnormal and normal tissues (i.e., TRIM) can achieve 
that goal.
Applications
This operator-blinded pilot study shows that TRIM is a rapid, highly accurate, 
and noninvasive method to identify individuals most likely to have polyps or 
cancers and thus to benefit from colonoscopy. If confirmed by subsequent 
studies, TRIM is likely to revolutionize colon cancer prevention programs.
Peer-review
This article reported the TRIMprob used to detect colon polys and cancers. 
TRIM present highly sensitivity and specificity. TRIMprob scanning is a valuable 
tool in diagnosing carcinoma of prostate, breast, gastric, rectal and so on. In 
this study, the authors compared TRIMprob with colonoscopy. It’s of clinical 
significance and convincing.
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